DN Decision Briefs / Platform evidence
Funding route, settlement chain and pool collateral are different decisions. This Arbitrum-focused GMX brief examines those boundaries, fee components, conditional exits and delegated trading permissions.
What Matters
Review of accessible provider documentation for GMX V2, focused on Arbitrum. Not a live trade, security audit, exhaustive market inventory or eligibility assessment.
Start with the market and pool, then check collateral, cost components and order conditions. A convenient funding route does not remove bridge, oracle or delegated-permission dependencies.
DN Evidence Block
The overview lists direct markets on Arbitrum, Avalanche and MegaETH. GMX Account access from supported source chains settles on Arbitrum.
Why it matters: Distinguish the funding chain from the execution chain. This brief focuses on Arbitrum; it does not inventory other deployments.
GMX trading overviewCollateral choices depend on the market and pool. The order guide gives BTC or USDC as choices for a BTC-USDC market. Non-stable collateral adds price exposure.
Why it matters: Confirm the pool, stored collateral and output token separately. A token accepted for funding is not proof that every pool accepts it as collateral.
GMX positions and order typesThe reviewed fee guide lists 0.04% or 0.06% position fees for most markets, depending on whether the action improves open-interest balance. TradFi exceptions apply.
Why it matters: Opening and closing are separate charged actions. Inspect price impact, swaps, funding, borrowing and network costs as well; a quoted fee is not total cost.
GMX feesGMX uses direction-dependent oracle bid/ask bounds for triggering and execution. The displayed midpoint is not the execution trigger, and fast moves can skip prices.
Why it matters: A chart touch does not prove the relevant trigger condition was met. DN has not measured trigger or fill reliability.
GMX positions and order typesThe liquidation guide says eligible stop-loss orders may be attempted first, but execution is not guaranteed when market moves and liquidation thresholds coincide.
Why it matters: Treat stop-loss protection as conditional. This brief establishes no safe leverage or guaranteed liquidation buffer.
GMX liquidations and ADLThe overview describes a locally stored sub-account key. Integration documentation describes expiry, action-count limits and removal of delegated access.
Why it matters: Review permission scope and revocation. Documentation of controls is not a DN audit of deployed permissions or browser security.
GMX trading overviewGMX delegated trading integrationThis documentation review does not establish individual eligibility, current regional restrictions or end-to-end operational availability.
Why it matters: No active trading CTA or ranking is supplied. Wallet connection and accessible documentation do not establish permission to trade.
GMX trading overviewEvidence boundary
No numerical all-in cost is calculated. A valid comparison needs contemporaneous quotes for matching assets, product modes, notional sizes, directions and holding periods, with entry, holding and exit costs included.
Your research record
The receipt preserves the provider sources and research gaps at version 1.0.0.
It is not a recommendation, approval, live quote or alert subscription. No account, balance, wallet or country is requested.
Change record
Initial Arbitrum-focused documentation brief. Distinguishes source chains from settlement, pool collateral from funding assets and documented controls from tested behaviour.
Review triggers: Changed provider documentation or deployment configuration; A substantiated correction; The 14-day editorial review deadline. No automated provider surveillance runs for this brief.
Provider-reported describes the source of a statement, not an independent endorsement. Unknown and not measured identify evidence gaps. A documentation review does not confer an operational-status classification or establish user eligibility.
DN has an existing GMX referral entry. This brief introduces no trading CTA and makes no operational-status or safety endorsement. Compensation does not affect evidence labels.
Educational research only, not investment, legal or tax advice. Leveraged derivatives can cause substantial losses.
